Case Investigations

Match Group, Inc.

February 3, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Match Group, Inc. (“Match” or the “Company”) (Nasdaq: MTCH) for potential violations of the federal securities laws.  Investors who purchased the Company’s common stock since the Company’s initial public offering of common stock on November 18, 2015 at $12 per share on may be affected.

Ooma Inc.

January 25, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Ooma Inc. ("Ooma” or the "Company") (NYSE: OOMA) for potential violations of the federal securities laws.  Investors who purchased Ooma common stock since the Company’s July 17, 2015 Initial Public Offering (the “IPO”)  may be affected.

Cnova NV

January 25, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Cnova NV ("Cnova” or the "Company") (Nasdaq: CNV) for potential violations of the federal securities laws.  Investors who purchased Cnova securities may be affected.

Sarepta Therapeutics

January 15, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Sarepta Therapeutics Inc. ("Sarepta” or the "Company") (Nasdaq: SRPT) for potential violations of the federal securities laws.  Investors who purchased shares of Sarepta common stock may be affected.

GoPro Inc.

January 14, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating GoPro Inc. (“GoPro” or the “Company”) (Nasdaq: GPRO) for potential violations of the federal securities laws.  Investors who purchased Company securities between July 21, 2015 and January 13, 2016 may be affected.

Fifth Street Asset Management, Inc.

January 12, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Fifth Street Asset Management, Inc. (“FSAM” or the “Company”) (NASDAQ: FSAM).  FSAM is a credit-focused asset manager and the investment advisor for Fifth Street Finance Corp. (“FSC”), Fifth Street Senior Floating Rate Corp. (“FSFR”), and various private Fifth Street funds. Investors who purchased shares of FSAM common stock in the Company’s October 29, 2014 initial public offering (“IPO”) or since the IPO may be affected.

Anavex Life Sciences Corporation

December 29, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Anavex Life Sciences Corporation (“Anavex” or the “Company”) (Nasdaq: AVXL) for potential violations of the federal securities laws.  Investors who purchased Company securities between October 25, 2015 and December 28, 2015 may be affected.

KaloBios Pharmaceuticals, Inc.

December 21, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating KaloBios Pharmaceuticals, Inc. ("KaloBios” or the “Company”) (NASDAQ: KBIO) for potential violations of the federal securities laws.  Investors who purchased KaloBios’ common stock may be affected.

Neothetics, Inc.

December 15, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Neothetics, Inc. (“Neothetics” or the “Company”) (NASDAQ: NEOT).  Neothetics is a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market. The Company’s lead product candidate, LIPO-202, is for the reduction of subcutaneous fat in the central abdomen (belly fat) in non-obese patients.  Investors who purchased shares of Neothetics common stock in the Company’s initial public offering (“IPO”) or since the IPO may be affected.

Barnes & Noble Education, Inc.

December 11, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Barnes & Noble Education, Inc. ("Barnes & Noble Education” or the "Company") (NYSE: BNED) for potential violations of the federal securities laws.  Investors who acquired or purchased Barnes & Noble Education securities since the Company’s August 2015 spin-out from Barnes &  Noble, Inc. (“Barnes & Noble”) may be affected.

United Development Funding IV

December 11, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating United Development Funding IV ("UDF IV" or the "Company") (Nasdaq: UDF), a Real Estate Investment Trust ("REIT"), for potential violations of the federal securities laws.  Investors who purchased UDF IV securities may be affected.

XBiotech, Inc.

November 24, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating XBiotech, Inc. ("XBiotech” or the "Company") (Nasdaq: XBIT) for potential violations of the federal securities laws.  Investors who purchased XBiotech securities since the Company’s April 14, 2015 initial public offering (“IPO”) may be affected.

Checkpoint Systems, Inc.

November 3, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Checkpoint Systems, Inc.. ("Checkpoint” or the "Company") (NYSE: CKP) for potential violations of the federal securities laws.  Investors who purchased Checkpoint securities may be affected.

Sonic Corp.

June 23, 2015 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating the Oklahoma City-based burger chain Sonic Corp (“Sonic”) (Nasdaq: SONC) for potential violations of the Federal Securities Laws. Purchasers of Sonic common stock between January 6, 2015 and June 22, 2015 may be affected.

St. Joseph Health System

San Francisco – February 14, 2014 - Kaplan Fox Investigates Claims Involving A Cyber Security Attack at St. Joseph Health System in Bryan, Texas.

AHMC Healthcare, Inc.

San Francisco – January 9, 2014 - Kaplan Fox & Kilsheimer LLP (“Kaplan Fox”) (www.kaplanfox.com) is investigating potential claims involving the theft of two laptops on October 12, 2013 from a secured office of AHMC Healthcare Inc....

Revel Casino Hotel

San Francisco – October 11, 2013 - Kaplan Fox & Kilsheimer LLP is investigating potential claims that the offer made to consumers by Revel Entertainment Group and Chatham Asset Management in the "Refund All Slot Losses" campaign, effective during the month of July, 2013 at the Revel Casino Hotel in Atlantic City, was misleading and deceptive.

Adobe Systems, Inc.

San Francisco – October 11, 2013 - Kaplan Fox & Kilsheimer LLP is investigating potential claims involving Adobe Systems Inc.’s public announcement on October 3, 2013 that it had discovered “sophisticated attacks” on its network, “involving the illegal access of customer information."

Crestor® (rosuvastatin calcium)

May 25, 2012 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating the statin drug Crestor® (rosuvastatin), a cholesterol-lowering medication, approved by the Food and Drug Administration for use by the public in August 2003.